JOP20200126A1 - طرق استخدام وتركيبات تحتوي على دولاجلوتيد - Google Patents
طرق استخدام وتركيبات تحتوي على دولاجلوتيدInfo
- Publication number
- JOP20200126A1 JOP20200126A1 JOP/2020/0126A JOP20200126A JOP20200126A1 JO P20200126 A1 JOP20200126 A1 JO P20200126A1 JO P20200126 A JOP20200126 A JO P20200126A JO P20200126 A1 JOP20200126 A1 JO P20200126A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- compositions containing
- dulaglutide
- containing dulaglutide
- doses
- Prior art date
Links
- 229960005175 dulaglutide Drugs 0.000 title abstract 3
- 108010005794 dulaglutide Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200126A1 true JOP20200126A1 (ar) | 2020-05-21 |
Family
ID=64572530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0126A JOP20200126A1 (ar) | 2017-11-21 | 2018-11-13 | طرق استخدام وتركيبات تحتوي على دولاجلوتيد |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11576950B2 (enExample) |
| EP (1) | EP3713593A2 (enExample) |
| JP (3) | JP7221956B2 (enExample) |
| KR (2) | KR20220146656A (enExample) |
| CN (2) | CN120478602A (enExample) |
| AU (2) | AU2018372709B2 (enExample) |
| BR (1) | BR112020007817A2 (enExample) |
| CA (1) | CA3082625A1 (enExample) |
| CL (1) | CL2020001252A1 (enExample) |
| CR (1) | CR20200202A (enExample) |
| DO (1) | DOP2020000104A (enExample) |
| EA (1) | EA202090971A1 (enExample) |
| EC (1) | ECSP20026436A (enExample) |
| IL (1) | IL274563B2 (enExample) |
| JO (1) | JOP20200126A1 (enExample) |
| MA (1) | MA50798A (enExample) |
| MX (1) | MX2020005231A (enExample) |
| PE (1) | PE20200847A1 (enExample) |
| PH (1) | PH12020550795A1 (enExample) |
| SG (1) | SG11202003687RA (enExample) |
| UA (1) | UA127588C2 (enExample) |
| WO (1) | WO2019103875A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7728176B2 (ja) * | 2019-03-15 | 2025-08-22 | イーライ リリー アンド カンパニー | 保存製剤 |
| MX2022009383A (es) * | 2020-01-30 | 2022-11-07 | Lilly Co Eli | Usos terapéuticos de dulaglutida. |
| EP4153130A1 (en) * | 2020-05-19 | 2023-03-29 | F. Hoffmann-La Roche AG | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| EA011166B1 (ru) | 2004-12-22 | 2009-02-27 | Эли Лилли Энд Компани | Композиции слитых белков-аналогов glp-1 |
| EA201070121A1 (ru) | 2007-07-10 | 2010-06-30 | Эли Лилли Энд Компани | Лекарственная форма, содержащая слитый белок glp-1-fc |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| JP7191043B2 (ja) | 2017-06-01 | 2022-12-16 | イーライ リリー アンド カンパニー | 慢性腎疾患の治療のためのデュラグルチド |
-
2018
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 CA CA3082625A patent/CA3082625A1/en active Pending
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt unknown
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 JO JOP/2020/0126A patent/JOP20200126A1/ar unknown
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/en active Pending
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/en not_active Ceased
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
-
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
-
2022
- 2022-02-01 JP JP2022014339A patent/JP2022062153A/ja active Pending
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
-
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891083A1 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| CA3024448C (en) | Modulatory polynucleotides | |
| GEP20227374B (en) | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
| EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201890052A1 (ru) | Регуляторы nrf2 | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| TW201613880A (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole | |
| EA201892123A1 (ru) | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj | |
| EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
| MX2021006977A (es) | Anellosomas y metodos de uso. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2019004580A (es) | Formulaciones farmaceuticas y metodos para prepararlas. | |
| MX2019005855A (es) | Formulaciones que se pueden pulverizar. | |
| MX2019011613A (es) | Formulaciones de acido 1-amino-1-ciclopropanocarboxilico. | |
| ZA202102816B (en) | High concentration protein formulation | |
| PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
| JOP20200126A1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد | |
| EA201892376A1 (ru) | Комбинированный состав трех противовирусных соединений | |
| EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| MX2020002793A (es) | Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados. | |
| EA201792093A1 (ru) | 2-тиопиримидиноны | |
| MX383460B (es) | Derivados peptidicos novedosos y sus usos. |